Fiche du document
- doi: 10.1002/acn3.493
- issn: 2328-9503
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/acn3.493
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29296621
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2328-9503
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_73E580433B396
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseasesCiter ce document
G. Perrotta et al., « Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits. », Serveur académique Lausannois, ID : 10.1002/acn3.493
Métriques
Partage / Export
Résumé
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.